IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Greece

  • ID: 1408483
  • Report
  • Region: Greece
  • 58 Pages
  • IMS Health
1 of 3

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets.

This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Note: Product cover images may vary from those shown
2 of 3

1. Healthcare System

  • Facts & Figures
  • Market Indicators
  • Provision & Funding
  • Background
  • Common Health Insurance Fund
  • Private Insurance
  • National Health Network
  • Uninsured
  • Healthcare Expenditure
  • Pharmaceutical Expenditure
  • State Debt

2. Pricing

  • Prescription Drugs
  • Application
  • Procedure
  • Appeals
  • EOPYY Price Negotiation Committee
  • Discounts and Rebates
  • Drug Price Bulletin
  • Drug Price Reviews
  • Generic Drugs
  • Generics with No Off-patent Version
  • Dynamic Pricing
  • Hospital Drugs
  • Pricing Regulations
  • E-Tenders
  • OTC Drugs

3. Reimbursement

  • Admission to Reimbursement
  • Positive List
  • Negative List
  • Reimbursement Categories
  • Reimbursement Prices
  • Therapeutic Reference Pricing
  • Active Ingredient-based Reference Pricing
  • Hospital Reimbursement
  • Formularies
  • Funding
  • High-cost Hospital Drugs
  • Changes in Reimbursement Status
  • Delisting
  • Removal of Reference Pricing Exemption
  • Changes in Reimbursement Prices
  • Price Reviews
  • Off-patent Branded Originals
  • Dynamic Pricing for Generics
  • Ad-hoc Price Cuts

4. Pharmacoeconomics

  • Pharmacoeconomic Requirements

5. Price Build Up

  • Wholesalers
  • Margins
  • Discounts
  • Background
  • Retail Pharmacies
  • Margins
  • Rebates
  • Discounts
  • Background
  • Dispensing Doctors
  • Sales Tax

6. Cost Containment

  • Industry Paybacks
  • Clawback
  • Direct-to-Pharmacy Distribution
  • Quarterly Rebates
  • Other Rebates
  • Electronic Reporting System for Rebates
  • Overdue Rebate Payments
  • Promotional Costs
  • Promotional Expenditure
  • Payments to Healthcare Professionals
  • SFEE Code of Ethics
  • Patient Co-payments
  • Out-patient Drugs
  • In-patient Drugs
  • Non-reimbursed Drugs
  • Healthcare
  • Prescribing Controls
  • Prescribing Limits
  • Prescribing Budgets
  • Generic Prescribing
  • Prior Authorisation
  • E-prescribing
  • Therapeutic Guidelines
  • Prescribing Restrictions
  • Off-label Prescribing
  • Time Limits
  • Generics
  • Rx-to-OTC Switches
  • Procedure
  • Liberalisation of OTCs
  • OTC Market
  • Parallel Trade

7. Future Developments

  • Outlook
  • Macroeconomic Situation
  • 2017 Agreement with Creditors
  • OTC Price Increases
  • Income Related Co-payments
  • Other Proposals
  • E-health

8. Names & Addresses

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll